Shingrix (Zostavax) Market 2026 expanding shingles vaccination

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Shingrix (Zostavax) Market During 2026–2030?

The growth observed in the historical period can be attributed to a heightened understanding of the complexities associated with shingles, an expanding global elderly demographic, the past shortcomings of live attenuated vaccines, the broadening of immunization protocols for seniors, and a rise in medical professional endorsements.

The anticipated growth during the forecast period stems from factors such as elevated targets for adult vaccination coverage, increased healthcare expenditure on preventive care, an expanding array of recombinant vaccine developments, a rise in government-backed immunization initiatives, and a heightened focus on mitigating the burden of post-herpetic neuralgia.

Key trends observed in the forecast period include the increasing incorporation of recombinant vaccine platforms, a heightened emphasis on adult immunization strategies, a growing requirement for durable shingles prevention, the broader implementation of optimized cold-chain vaccine distribution, and a reinforced commitment to vaccine safety and efficacy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20264&type=smp

What Underlying Factors Are Accelerating The Growth Of The Shingrix (Zostavax) Market?

The increasing acceptance of vaccination is anticipated to drive expansion in the shingrix (zostavax) market moving ahead. This medical procedure involves giving a vaccine to prompt the body’s defenses to identify and combat particular disease-causing agents. The rise in vaccination uptake stems from greater understanding of its efficacy in disease prevention, lessening the impact of illness, and the creation of secure and readily available vaccines. Furthermore, widespread acceptance is supported by public health efforts, enhanced medical facilities, and worldwide vaccination programs. Shingrix (Zostavax) plays a crucial role in vaccination by offering robust protection against shingles and associated complications. Its benefits are especially notable for individuals aged 50 and above, as it substantially lowers the likelihood of shingles returning and the development of post-herpetic neuralgia. An illustrative example, a May 2024 study from the Journal of the American Medical Association (JAMA), a US-based peer-reviewed medical journal, indicated a 46% increase in shingles vaccinations covered by Medicare Part D in the year following the IRA policy’s implementation in January 2023. Consequently, the increasing adoption of vaccination is propelling the expansion of the shingrix (zostavax) market.

How Are The Various Segments Of The Shingrix (Zostavax) Market Categorized?

The shingrix (zostavax) market covered in this report is segmented –

1) By Formulation: Recombinant Vaccine (Shingrix), Live Attenuated Vaccine (Zostavax)

2) By Indication: Shingles Prevention, Post-Herpetic Neuralgia

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy

What Trends Are Affecting The Expansion Of The Shingrix (Zostavax) Market?

Leading enterprises within the shingrix (zostavax) market are concentrating on developing innovative solutions, including non-live, recombinant subunit adjuvanted vaccines, to satisfy the increasing demand for safer and more effective immunization. This focus is particularly driven by age-related immune decline and the necessity for suitable options for immunocompromised populations. A non-live, recombinant subunit adjuvanted vaccine is characterized by containing specific protein components (antigens) of a pathogen, paired with an adjuvant to amplify the immune response, contrasting with traditional live-attenuated vaccines which utilize weakened forms of the entire virus. For example, in 2023, GSK plc, a UK-based biopharmaceutical company, launched Shingrix (Recombinant Zoster Vaccine, RZV) in India. This specific vaccine is non-live, administered intramuscularly in two doses, and is composed of the glycoprotein E antigen along with GSK’s proprietary AS01B adjuvant system. Shingrix effectively stimulates a robust and enduring immune response, thereby overcoming the natural decline in immunity observed in older adults, and demonstrates very high efficacy of up to ~97%.

Which Major Firms Influence Developments In The Shingrix (Zostavax) Market?

Major companies operating in the shingrix (zostavax) market are GSK plc

Read the full shingrix (zostavax) market report here:

https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report

Which Region Is Projected To Dominate The Shingrix (Zostavax) Market During The Forecast Period?

North America was the largest region in the shingrix (zostavax) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Shingrix (Zostavax) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20264&type=smp

Browse Through More Reports Similar to the Global Shingrix (Zostavax) Market 2026, By The Business Research Company

Varenicline Market Report 2026

https://www.thebusinessresearchcompany.com/report/varenicline-global-market-report

Feed Premix Market Report 2026

https://www.thebusinessresearchcompany.com/report/feed-premix-global-market-report

Zinc Battery Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-battery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795